AU2017247004B2 - Method of treating atherosclerosis - Google Patents

Method of treating atherosclerosis Download PDF

Info

Publication number
AU2017247004B2
AU2017247004B2 AU2017247004A AU2017247004A AU2017247004B2 AU 2017247004 B2 AU2017247004 B2 AU 2017247004B2 AU 2017247004 A AU2017247004 A AU 2017247004A AU 2017247004 A AU2017247004 A AU 2017247004A AU 2017247004 B2 AU2017247004 B2 AU 2017247004B2
Authority
AU
Australia
Prior art keywords
seq
set forth
sequence set
fxii
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017247004A
Other languages
English (en)
Other versions
AU2017247004A1 (en
Inventor
Yung-Chih Chen
Hamid HOSSEINI
Con Panousis
Karlheinz Peter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of AU2017247004A1 publication Critical patent/AU2017247004A1/en
Application granted granted Critical
Publication of AU2017247004B2 publication Critical patent/AU2017247004B2/en
Priority to AU2022241636A priority Critical patent/AU2022241636B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43568—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from wasps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Insects & Arthropods (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017247004A 2016-04-06 2017-04-06 Method of treating atherosclerosis Active AU2017247004B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022241636A AU2022241636B2 (en) 2016-04-06 2022-10-04 Method of treating atherosclerosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16164009.9 2016-04-06
EP16164009 2016-04-06
PCT/AU2017/050297 WO2017173494A1 (en) 2016-04-06 2017-04-06 Method of treating atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022241636A Division AU2022241636B2 (en) 2016-04-06 2022-10-04 Method of treating atherosclerosis

Publications (2)

Publication Number Publication Date
AU2017247004A1 AU2017247004A1 (en) 2018-11-22
AU2017247004B2 true AU2017247004B2 (en) 2022-07-07

Family

ID=55759460

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017247004A Active AU2017247004B2 (en) 2016-04-06 2017-04-06 Method of treating atherosclerosis
AU2022241636A Active AU2022241636B2 (en) 2016-04-06 2022-10-04 Method of treating atherosclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022241636A Active AU2022241636B2 (en) 2016-04-06 2022-10-04 Method of treating atherosclerosis

Country Status (8)

Country Link
US (2) US11174321B2 (OSRAM)
EP (1) EP3440107A4 (OSRAM)
JP (2) JP7456723B2 (OSRAM)
KR (2) KR20230136687A (OSRAM)
CN (1) CN109071629A (OSRAM)
AU (2) AU2017247004B2 (OSRAM)
CA (1) CA3019851A1 (OSRAM)
WO (1) WO2017173494A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
KR20230136687A (ko) * 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법
BR112020011240A2 (pt) * 2017-12-15 2020-11-24 Csl Limited uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica
WO2020248024A1 (en) * 2019-06-12 2020-12-17 CSL Innovation Pty Ltd Soluble complement receptor type 1 variant conjugates and uses thereof
CA3159675A1 (en) * 2019-12-03 2021-06-10 Ingo Pragst Use of an anti-factor xii antibody for the treatment or prevention of hereditary angioedema
CA3183508A1 (en) * 2020-07-03 2022-01-06 Michael Johnston High concentration formulation of factor xii antigen binding proteins
WO2022235551A2 (en) * 2021-05-03 2022-11-10 President And Fellows Of Harvard College Fc-fusion protein therapeutic for the treatment of pancreatitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) * 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
JP2007503838A (ja) 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス， インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
AU2005318464B2 (en) 2004-12-23 2012-02-23 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
JP2010518039A (ja) 2007-02-12 2010-05-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
CN102369021B (zh) 2008-12-19 2016-09-07 宏观基因有限公司 共价双抗体及其用途
LV14606B (lv) 2011-05-17 2013-01-20 Tetra, Sia Jauns XII faktora inhibitors
RS66465B1 (sr) * 2011-07-22 2025-02-28 Csl Behring Gmbh Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe
JP5653860B2 (ja) * 2011-07-28 2015-01-14 富士フイルム株式会社 管壁の硬度測定方法および装置
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
PL3013366T3 (pl) * 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
KR20230136687A (ko) * 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOCH M., "Role of Coagulation Factor XII in Atherosclerosis", Doctoral thesis, (2014), URL: https://opus.bibliothek.uni-wuerzburg.de/opus4-wuerzburg/files/9785/Dissertation_Miriam_Koch.pdf *

Also Published As

Publication number Publication date
EP3440107A1 (en) 2019-02-13
AU2022241636B2 (en) 2025-11-13
KR20230136687A (ko) 2023-09-26
US20190309089A1 (en) 2019-10-10
EP3440107A4 (en) 2020-02-19
US20220017638A1 (en) 2022-01-20
US11174321B2 (en) 2021-11-16
JP7456723B2 (ja) 2024-03-27
WO2017173494A1 (en) 2017-10-12
JP2019513748A (ja) 2019-05-30
CN109071629A (zh) 2018-12-21
KR20180132831A (ko) 2018-12-12
CA3019851A1 (en) 2017-10-12
AU2022241636A1 (en) 2022-10-27
JP2022116154A (ja) 2022-08-09
AU2017247004A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
AU2022241636B2 (en) Method of treating atherosclerosis
JP6669800B2 (ja) Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
KR102448456B1 (ko) 인자 xi의 활성 부위에 대한 모노클로날 항체 및 이의 용도
KR20190035796A (ko) 다양한 질환 및 장애의 치료를 위해 masp-3을 억제하는 조성물 및 방법
WO2012168491A1 (en) Pharmaceutical formulations of pcsk9 antagonists
US20220305133A1 (en) Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof
KR20230035355A (ko) 인자 xii 항원 결합 단백질의 고농도 제형
CN115335077A (zh) 用于治疗和/或预防与造血干细胞移植相关的特发性肺炎综合征（ips）和/或毛细血管渗漏综合征（cls）和/或植入综合征（es）和/或液体超负荷（fo）的方法
HK1220132B (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)